Aug 2026· Frontiers in Pharmacology· Vol 17· 0 citations· 63 references
Medicine
TL;DR
The synergy of AI and DILI toxicogenomics has transitioned the discipline from descriptive profiling toward mechanism-driven predictive toxicology, highlighting toxicogenomics as a primary driver of advancement in this field of high-dimensional omics research.
Abstract
Drug-induced liver injury (DILI) is a critical safety issue in drug development, characterized by its idiosyncratic nature, complex mechanisms, and poor predictability in standard preclinical models. High-dimensional omics strategies, particularly toxicogenomics, have attracted increased interest in addressing the complexity of hepatotoxicity, especially in the context of emerging artificial intelligence (AI) technologies. This review traces the evolution of AI and machine learning (ML) within DILI-related omics research, highlighting toxicogenomics as a primary driver of advancement in this field. We first explore the early studies in computational toxicogenomics, which primarily focused on exploratory approaches, utilizing clustering, time-series, co-expression, and basic pathway analyses to identify molecular signatures indicative of nascent liver injury. We then examine how the adoption of supervised machine learning enabled robust predictive modeling, facilitating systematic feature selection, signature refinement, and rigorous validation. More recently, the field has been further transformed by deep learning, biologically informed network architectures, and generative artificial intelligence. Across these methodological eras, AI has enhanced mechanistic interpretation by identifying biologically relevant signatures, integrating multimodal evidence, and strengthening evidence for established DILI mechanisms, including oxidative stress, mitochondrial dysfunction, altered xenobiotic metabolism, inflammation, and cell death. Ultimately, the synergy of AI and DILI toxicogenomics has transitioned the discipline from descriptive profiling toward mechanism-driven predictive toxicology.
INTRODUCTION
Predicting drug-induced toxicity remains one of the principal bottlenecks in drug development: in vivo and in vitro assays are resource-intensive, and their concordance with human-specific toxicity is often limited. Toxicogenomics addresses this gap by linking chemical exposure to gene-expression and pathw...
Baseerat Fatima, Minal Zaka, Maham Ashraf et al.· Toxicology Mechanisms and Me...· 0 citations
The significance of AI-based toxicogenomics in drug development, environmental contaminant screening, and regulatory toxicology, while addressing key challenges such as data heterogeneity, model interpretability, and regulatory acceptance is discussed.
Mohammed Monirul Islam, Sibghatullah Muhammad Ali Sangi, Girish Meravanige et al.· Frontiers in Genetics· 0 citations
This study introduces the virtual toxicity network (vToxiNet), a biologically constrained deep learning framework that embeds systems toxicology knowledge directly into neural network architecture for interpretable hepatotoxicity prediction and supports further development of mechanism-informed approaches for chemical...
Xue-Lian Jia, Tong Wang, Daniel P. Russo et al.· Journal of Hazardous Materia...· 0 citations
Artificial intelligence needs to be used to support instead of supplanting human expertise, supporting informed, patient-centered decision making and generating innovative, ethical healthcare solutions.
Prasad Hemant Mahajan, Mahalaxmi Mohan· Asian Journal of Pharmaceuti...· 0 citations
The accurate prediction of chemical toxicity remains a major challenge in drug development and chemical safety assessment because conventional approaches can be costly, time-consuming, ethically constrained, and limited in predictive performance. This review examines how artificial intelligence (AI), particularly machi...
Ahmed Hagag, Nada A. Elsayed, Ibrahim Abdelbaky· Frontiers in Bioinformatics· 0 citations
This review discusses how AI can accelerate computational drug discovery, virtual screening (VS), and the repurposing of already-approved medications, and it can also optimize combination therapies through computational simulation.
D. Bhagwat, Sonali A. Chikhalwale, S. Mali et al.· Current pharmaceutical desig...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.